Related references
Note: Only part of the references are listed.MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines
Giuditta Viticchie et al.
CELL CYCLE (2011)
microRNA-203 suppresses bladder cancer development by repressing bcl-w expression
Juanjie Bo et al.
FEBS JOURNAL (2011)
Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib
Michael Koldehoff et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Protein Kinase C-Dependent Upregulation of miR-203 Induces the Differentiation of Human Keratinocytes
Eniko Sonkoly et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells
Marina Chekulaeva et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression
Maria J. Bueno et al.
CANCER CELL (2008)
Control of cell proliferation pathways by microRNAs
Maria Jose Bueno et al.
CELL CYCLE (2008)
MicroRNA expression and function in cancer
Ramiro Garzon et al.
TRENDS IN MOLECULAR MEDICINE (2006)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment
JM Goldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)
L Wohlbold et al.
BLOOD (2003)
Imatinib mesylate in the treatment of chronic myeloid leukaemia
BJ Druker
EXPERT OPINION ON PHARMACOTHERAPY (2003)
Specific inhibition of bcr-abl gene expression by small interfering RNA
M Scherr et al.
BLOOD (2003)
Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi)
M Wilda et al.
ONCOGENE (2002)
microRNAs: Tiny regulators with great potential
V Ambros
CELL (2001)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Share Paper
